Science Abstracts
SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies
March 2010
March 2010
Authors : Lauren C Pinter-Brown
Affliation : Clinical Professor of Medicine, Geffen School of Medicine at UCLA, Director, UCLA Lymphoma Program, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA ; ; lpinterbrown@mednet.ucla.edu
DOI : 10.1517/13543780802493440
Published in : Expert Opin. Investig. Drugs
Subject:
Keywords: anaplastic large-cell lymphoma , CD30 , CD30-positive lymphoproliferative disorder , chimeric antibody , Hodgkin lymphoma , lymphoma , lymphomatoid papulosis , SGN-30 , SGN-35
Abstract
Please Login to read the full article.
RELATED CONTENT
NEWS
- Genmab starts trial of Arzerra vs rituximab in non-Hodgkin's lymphoma
- First drug approval for Genmab with Arzerra for leukaemia in the US
- Seattle Genetics taps Takeda as partner for lead antibody-drug conjugate
- US FDA panel backs Gloucester's Istodax for cutaneous T-cell lymphoma
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
